Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Hold” from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has received an average rating of “Hold” from the twenty-eight research firms that are presently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and nine have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $32.2963.

SRPT has been the subject of several recent analyst reports. Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a report on Thursday. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Royal Bank Of Canada increased their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research report on Thursday, January 8th. Citigroup lifted their price target on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research note on Thursday. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $21.68 on Friday. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $73.95. The company has a current ratio of 2.32, a quick ratio of 1.48 and a debt-to-equity ratio of 0.73. The stock has a market cap of $2.28 billion, a P/E ratio of -2.57, a price-to-earnings-growth ratio of 0.37 and a beta of 0.42. The stock has a 50 day moving average of $18.71 and a 200-day moving average of $19.97.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). The company had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The firm’s quarterly revenue was down 32.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.90 EPS. On average, analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, Director Stephen Mayo sold 7,239 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the sale, the director directly owned 1,765 shares in the company, valued at approximately $30,040.30. The trade was a 80.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 214.2% in the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 3,671 shares during the period. Great Lakes Advisors LLC bought a new position in Sarepta Therapeutics in the first quarter worth about $224,000. PNC Financial Services Group Inc. boosted its stake in Sarepta Therapeutics by 61.8% in the second quarter. PNC Financial Services Group Inc. now owns 3,779 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 1,444 shares during the period. Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 3.0% in the second quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock valued at $32,085,000 after acquiring an additional 55,076 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of Sarepta Therapeutics by 10.6% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,250 shares of the biotechnology company’s stock valued at $432,000 after purchasing an additional 2,417 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 siRNA results point to target knockdown, muscle exposure and tolerability for SRP‑1001 and SRP‑1003 — the primary catalyst behind the rally. Business Wire: Sarepta Announces First Clinical Data
• Positive Sentiment: Multiple outlets and market commentators highlight the clinical readouts as a potential turning point; coverage helped drive heavy volume and momentum into the stock. Yahoo Finance: SRPT Stock Surges
• Positive Sentiment: Some sell‑side moves reflected renewed conviction — Morgan Stanley is reported to have raised its price target (reported widely alongside the trial coverage), which helped fuel the rally. InsiderMonkey: Morgan Stanley PT Hike
• Positive Sentiment: Unusually heavy options and call buying accompanied the move, indicating speculative bullish positioning and short‑term leverage from traders.
• Neutral Sentiment: Several valuation and note‑style writeups are trying to size the opportunity vs. risk — analysts and outlets caution that early Phase 1/2 data need confirmation and that valuation debate will drive near‑term swings. Yahoo/Zacks coverage: Is Further Upside Left?
• Negative Sentiment: Some firms remain skeptical — Citigroup raised a price target modestly but kept a sell rating (cites downside from current levels), and Needham reaffirmed an underperform stance, keeping sell‑side views polarized. Benzinga: Analyst Ratings
• Negative Sentiment: Independent analysts and commentators warn the data are early — some outlets argue it’s too soon to extrapolate durable clinical or commercial success from small Phase 1/2 cohorts. Seeking Alpha: Too Early to Get Excited
• Negative Sentiment: Underlying fundamentals and priorquarter results (recent EPS miss and revenue decline vs. year‑ago) remain a drag on sentiment; this increases the chance of volatility if follow‑up data or guidance disappoints.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.